Robert E. Conway - Jan 30, 2024 Form 4 Insider Report for ARCA biopharma, Inc. (ABIO)

Role
Director, Chairman of the Board
Signature
/s/ C. Jeffrey Dekker, Attorney-in-Fact
Stock symbol
ABIO
Transactions as of
Jan 30, 2024
Transactions value $
$0
Form type
4
Date filed
1/31/2024, 04:25 PM
Previous filing
Jan 4, 2024
Next filing
May 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ABIO Common Stock 50K Jan 30, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABIO Stock Option (right to buy) Award $0 +6K $0.00 6K Jan 30, 2024 Common Stock 6K $1.64 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 30, 2024, subject to the Reporting Person continuing to provide Continuous Service (as defined in the 2020 Equity Incentive Plan) through such date. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested.